18 окт. 2023 г. · PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis ...

The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ...

PURPOSE 1-5 is the most comprehensive and diverse program for an investigational HIV PrEP program ever conducted. More information about the PURPOSE program can ...

22 июн. 2024 г. · Gilead Sciences announced that no HIV infections had been seen among 2134 young women and adolescent girls in South Africa and Uganda given twice-yearly ...

PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV PrEP in France and the United Kingdom.

Injectable lenacapavir (LEN) is an investigational antiretroviral (ARV) drug that is being studied as a potential PrEP product.

19 окт. 2023 г. · The Phase II PURPOSE 5 trial will evaluate the persistence of the therapy against emtricitabine/tenofovir disoproxil fumarate (F/TDF) in ...

Find more resources to learn more about the PURPOSE trials. Read additional information through the provided linked presentations and publications.

The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ...

Purpose: The purpose of this study is to evaluate the pharmacokinetics of twice-yearly subcutaneous lenacapavir and to assess the safety of twice-yearly ...